ArticleFrontiers in molecular biosciences2025
Garlic oil-loaded nanodisks for the amelioration of acute lung injury via modulation of the NF-κB and Keap1-Nrf2 axis.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Essential Oil-Loaded Lipid Nanocarriers with Anti-Inflammatory Activity: Quality Control, Safety, and Efficacy.Biomedicines · 2026Review
- NO-Responsive Oleanolic Acid Self-Assembled Micelles Co-Loaded with BAY 11-7082 for Synergistic Chondroprotection and Anti-Osteoarthritis Therapy.Bioengineering (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are prevalent and severe respiratory conditions with high morbidity and mortality rates, and specific treatment modalities are lacking. Garlic oil (GO), which is rich in sulfur compounds, has diverse biological properties, including anti-inflammatory and antioxidant effects; nonetheless, its utility is hindered by its limited water solubility and bioavailability. Nanotechnology-based formulations offer a promising solution to enhance GO efficacy. The aim of this investigation was to elucidate the protective effect and underlying mechanism of GO nanodisks (GO-nanodisks) on lipopolysaccharide (LPS)-induced acute lung injury. Methods: We developed a novel prescription utilizing GO-nanodisks. An acute lung injury model was induced in mice through LPS administration. The mice were randomly allocated into groups: healthy untreated, positive control, GO (50 mg/kg), and GO-nanodisks (50 mg/kg). Tail vein injections were administered accordingly. Subsequent assessments included lung histopathology; inflammatory cytokine (TNF-α, IL-6, IL-4, and IL-10) levels; oxidative stress marker (MDA, SOD, T-AOC, NO, and CAT) levels; and protein expression analyses. Results: This study successfully developed GO-nanodisks using a novel fabrication method. The GO-nanodisks demonstrated favorable physicochemical characteristics, with a mean particle diameter of 148 ± 3 nm, a polydispersity index (PDI) of 0.15 ± 0.02, a zeta potential of -0.2 ± 0.1 mV, and an encapsulation efficiency of 55.26% ± 0.04%. Compared with the positive control group, the GO-nanodisk group presented significantly reduced lung tissue pathology, lower inflammatory factor levels, and an improved oxidative stress status. Furthermore, the GO-nanodisk group displayed Keap1/Nrf2 signaling pathway activation and NF-kappa B pathway inhibition, surpassing the efficacy of the GO group. Conclusion: The results of this study demonstrate that the nanodisks formulation developed in this work effectively enables stable encapsulation of GO, enhances its bioavailability, and improves its protective efficacy against LPS-induced ALI. Furthermore, this formulation provides a promising theoretical foundation for the encapsulation of oil-based pharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.